What's Happening?
Jazz Pharmaceuticals is actively recruiting for a Director, Global Value and Health Economics and Outcomes Research (HEOR) in Philadelphia, PA. This leadership role is critical for defining and executing global and U.S. payer evidence strategies for pipeline
assets, spanning from early clinical development (Phase 2/3) through global regulatory approval and launch. The director will lead global payer evidence generation while simultaneously serving as the U.S. HEOR lead, overseeing all U.S. pre-launch HEOR deliverables, payer field enablement tools, and U.S. market access evidence strategies. The position requires a dual mandate, acting as a strategic evidence engine to validate the value story developed by Global and U.S. Market Access teams. Key responsibilities include integrating payer and HTA requirements into clinical trial designs, developing advanced health economic modeling strategies, and leading U.S. pre-launch HEOR initiatives such as AMCP Pre-Approval Information Exchange (PIE) dossiers and budget impact models. The role also involves close collaboration with EU/INT HEOR teams for HTA evidence strategies and analytical packages.
Why It's Important?
This recruitment highlights the increasing importance of health economics and outcomes research in the biopharmaceutical industry, particularly for market access and product valuation. The dual global and U.S. focus of the role underscores the complex regulatory and market landscapes pharmaceutical companies must navigate to ensure successful product launches and patient access. For Jazz Pharmaceuticals, securing a leader in this area is crucial for substantiating the value of its pipeline assets, especially in rare diseases where evidentiary challenges are significant. The role's emphasis on integrating payer requirements early in clinical development can lead to more efficient trial designs and stronger evidence packages, ultimately influencing formulary decisions by commercial health plans, Medicare, and Medicaid. This strategic approach can accelerate patient access to new therapies and optimize commercial success in a highly competitive and regulated environment.
What's Next?
Jazz Pharmaceuticals will proceed with the recruitment process to fill this critical Director position. Once appointed, the new director will immediately begin shaping the HEOR strategy for Jazz's pipeline assets, focusing on integrating payer evidence requirements into ongoing and future clinical trials. This will involve close collaboration with clinical development, market access, and medical affairs teams to ensure a cohesive approach to evidence generation and value communication. The director will also be instrumental in preparing for upcoming product launches by developing comprehensive U.S. pre-launch HEOR deliverables and supporting global HTA submissions. The successful integration of this role is expected to enhance Jazz Pharmaceuticals' ability to demonstrate the value of its innovative therapies to payers and healthcare systems, potentially leading to broader market access and improved patient outcomes.
Beyond the Headlines
The demand for specialized HEOR expertise, as evidenced by this job opening, reflects a broader industry trend towards value-based healthcare. Payers are increasingly scrutinizing the economic and clinical value of new drugs, moving beyond efficacy alone. This shift necessitates robust evidence generation that demonstrates not only clinical benefits but also cost-effectiveness and real-world impact. For rare diseases, where patient populations are small and clinical trial data can be limited, the role of HEOR is even more critical in developing innovative approaches to evidence generation, such as leveraging natural history studies and real-world data. The strategic importance of this role also points to the growing influence of health technology assessments (HTAs) globally, requiring companies to develop adaptable evidence packages that meet diverse national requirements. This trend will likely continue to drive demand for professionals who can bridge the gap between clinical science, economics, and market access.
